Healthcare

Amedisys Sees Home Health Revenue Rise While UnitedHealth Deal Hangs In The Balance

Amedisys (Nasdaq: AMED) exceeded Wall Street expectations in its first-quarter results for 2025. The company’s home health segment benefited from increased volume and higher rates, while its high-acuity care segment reached a milestone with record admissions.

However, Amedisys stock remained relatively flat amid ongoing scrutiny of the Baton Rouge, Louisiana-based company’s proposed merger with UnitedHealth Group (UHG) (NYSE: UNH), which is currently under investigation by the U.S. Department of Justice (DOJ) for potential antitrust issues.

The company reported net Q1 revenue of $594.8 million, a 4.1% increase from the previous year, alongside a notable 21.4% rise in adjusted earnings per share. Amedisys also reported net income of $61 million and adjusted EBITDA of $68.8 million, an increase from $59.9 million in 2024.

In Q1, Amedisys’ home health services generated net service revenues of $372.1 million, marking a 5.8% year-over-year increase. Medicare revenues totaled $212.1 million within this segment, a 2.7% decline from the previous year. 

Non-Medicare revenues experienced nearly a 20% year-over-year increase, reaching $160 million. Amedisys’s high-acuity care segment reported net service revenues of $7.7 million, up from $4.4 million in Q1 2024.

UHG Merger update

In early April, Home Health Care News reported that the DOJ lawsuit against Amedisys and UHG will go to mediation on Aug. 18.

The DOJ sued the companies in November 2024 to block UHG subsidiary Optum from acquiring Amedisys following Optum’s agreement to purchase the company in June 2023 for $3.3 billion. Last summer, the DOJ initiated an investigation into the deal.

The DOJ reports that its primary concern is the potential for reduced competition in the home health and hospice sectors. According to the lawsuit, if the merger is completed, Optum could control over 30% of home health and hospice services in eight states. This deal would also expand Optum’s presence into five additional states.

UnitedHealth Group (UHG) is one of the largest companies in the country, with various associated business lines. Optum owns LHC Group, a major player in home-based care.

This is not the end of UHG’s legal troubles. In February, the DOJ initiated a civil fraud investigation into the company’s practices for recording diagnoses that trigger extra payments to its Medicare Advantage (MA) plans.

UHG’s UnitedHealthcare is the largest MA provider in the U.S., accounting for 29% of total MA enrollment in 2024, according to KFF.

The post Amedisys Sees Home Health Revenue Rise While UnitedHealth Deal Hangs In The Balance appeared first on Home Health Care News.

Picture of John Doe
John Doe

Sociosqu conubia dis malesuada volutpat feugiat urna tortor vehicula adipiscing cubilia. Pede montes cras porttitor habitasse mollis nostra malesuada volutpat letius.

Related Article

Leave a Reply

Your email address will not be published. Required fields are marked *

X
"Hello! Let’s get started on your journey with us."
Site SearchBusiness ServicesBusiness Services

Meet Eve: Your AI Training Assistant

Welcome to Enlightening Methodology! We are excited to introduce Eve, our innovative AI-powered assistant designed specifically for our organization. Eve represents a glimpse into the future of artificial intelligence, continuously learning and growing to enhance the user experience across both healthcare and business sectors.

In Healthcare

In the healthcare category, Eve serves as a valuable resource for our clients. She is capable of answering questions about our business and providing "Day in the Life" training scenario examples that illustrate real-world applications of the training methodologies we employ. Eve offers insights into our unique compliance tool, detailing its capabilities and how it enhances operational efficiency while ensuring adherence to all regulatory statues and full HIPAA compliance. Furthermore, Eve can provide clients with compelling reasons why Enlightening Methodology should be their company of choice for Electronic Health Record (EHR) implementations and AI support. While Eve is purposefully designed for our in-house needs and is just a small example of what AI can offer, her continuous growth highlights the vast potential of AI in transforming healthcare practices.

In Business

In the business section, Eve showcases our extensive offerings, including our cutting-edge compliance tool. She provides examples of its functionality, helping organizations understand how it can streamline compliance processes and improve overall efficiency. Eve also explores our cybersecurity solutions powered by AI, demonstrating how these technologies can protect organizations from potential threats while ensuring data integrity and security. While Eve is tailored for internal purposes, she represents only a fraction of the incredible capabilities that AI can provide. With Eve, you gain access to an intelligent assistant that enhances training, compliance, and operational capabilities, making the journey towards AI implementation more accessible. At Enlightening Methodology, we are committed to innovation and continuous improvement. Join us on this exciting journey as we leverage Eve's abilities to drive progress in both healthcare and business, paving the way for a smarter and more efficient future. With Eve by your side, you're not just engaging with AI; you're witnessing the growth potential of technology that is reshaping training, compliance and our world! Welcome to Enlightening Methodology, where innovation meets opportunity!

[wpbotvoicemessage id="402"]